NEW YORK (360Dx) – Xifin today announced a deal with PWNHealth aimed at improving access to laboratory and other services in support of direct-to-consumer diagnostic testing.
Under the deal, Xifin will market PWNHealth's services as a complementary offering to Xifin's health solutions, including Xifin RPM, a billing solution for diagnostic service providers. Xifin customers will be able to access lab services in support of consumer-initiated testing and employer-based screening programs. Its customers will also be able to access pre- and post-test telegenetic counseling services through PWNHealth's 50-state network of physicians and counselors.
PWNHealth's clinical team and clinical advisory board evaluate tests for validity and utility in a clinical setting, and a protocol is used to determine "exclusion criteria, and when care interventions and medical counsel are required," Xifin said in a statement.
"Today's labs require services that help empower all major stakeholders — including consumers, providers, and employers — to improve healthcare outcomes and costs," PWNHealth CEO Sanjay Pingle said in a statement. "As a result of our collaboration, Xifin can help its lab customers bridge service gaps and pursue growth opportunities that reach all of these markets."
Financial and other terms of the agreement were not disclosed.